Oncotarget

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 11. View the complete issue: https://www.oncotarget.com/archive/v12/i11/ COVER PAPER: “CEA as a blood-based biomarker in anal cancer” https://doi.org/10.18632/oncotarget.27959 NEWS: “FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?” https://doi.org/10.18632/oncotarget.27957 (PDF Download) EDITORIAL: “Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response” https://doi.org/10.18632/oncotarget.27927 (PDF Download) EDITORIAL: “Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?” https://doi.org/10.18632/oncotarget.27931 (PDF Download) RESEARCH PAPER: “Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab” https://doi.org/10.18632/oncotarget.27965 RESEARCH PAPER: “Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma” https://doi.org/10.18632/oncotarget.27964 RESEARCH PAPER: “A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation” https://doi.org/10.18632/oncotarget.27962 RESEARCH PAPER: “Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network” https://doi.org/10.18632/oncotarget.27963 RESEARCH PAPER: “Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma” https://doi.org/10.18632/oncotarget.27961 REVIEW: “Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment” https://doi.org/10.18632/oncotarget.27929 CASE REPORT: “Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review” https://doi.org/10.18632/oncotarget.27966 Keywords - anal cancer, prostate cancer, colorectal cancer, lung cancer, breast cancer, exosomes, cell proliferation, Tau protein, Alzheimer’s disease, DNA repair, advanced squamous cell carcinoma, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Skin cancer is common but preventable with UV exposure being a major risk factor. Basal cell carcinoma is the most treatable, while melanoma is the most serious due to its tendency to spread. 30% of melanoma cases may not be related to UV exposure. Oncotarget's special collection focuses on skin cancer research.

Trending research paper discusses the role of RNA modification regulatory proteins in melanoma. Study analyzes genetic alterations and RNA overexpression in melanoma samples. Potential therapeutic targets identified through bioinformatics analysis. Proteins MET-TL4 and DNM-T3A implicated in melanoma growth and drug resistance.

Learn how Impact Journals prioritize scientific integrity in scholarly publishing through ethics statements, industry standards, peer review, plagiarism elimination, and post-publication investigations. Explore their advanced image forensics service and commitment to upholding quality in biomedical science publishing.

Researchers discuss the inhibitory effects of Tomivosertib in AML, highlighting its ability to suppress eIF4E phosphorylation, decrease leukemic cell survival, and enhance the efficacy of venetoclax. The study focuses on regulating the eIF4E binding protein to overcome drug resistance in AML treatment.

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 10. View the complete issue: https://www.oncotarget.com/archive/v12/i10/ COVER PAPER: “Inhibitory effects of Tomivosertib in acute myeloid leukemia” https://doi.org/10.18632/oncotarget.27952 EDITORIAL: “Raman spectroscopy determination of the mineral characteristics of microcalcifications in breast cancer, a way towards an improved screening approach” https://doi.org/10.18632/oncotarget.27912 (PDF Download) EDITORIAL: “Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis” https://doi.org/10.18632/oncotarget.27913 (PDF Download) RESEARCH PAPER: “Genome wide DNA methylation landscape reveals glioblastoma’s influence on epigenetic changes in tumor infiltrating CD4+ T cells” https://doi.org/10.18632/oncotarget.27955 RESEARCH PAPER: “Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity” https://doi.org/10.18632/oncotarget.27953 RESEARCH PAPER: “Perioperative changes in the plasma metabolome of patients receiving general anesthesia for pancreatic cancer surgery” https://doi.org/10.18632/oncotarget.27956 RESEARCH PAPER: “Transcriptome analyses of urine RNA reveal tumor markers for human bladder cancer: validated amplicons for RT-qPCR-based detection” https://doi.org/10.18632/oncotarget.27954 Keywords - acute myeloid leukemia, breast cancer, bladder cancer, leukemia, DNA methylation, tumor, glioblastoma, miRNA, skin toxicity, pancreatic cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Exploring the significance of IGF-CTP composite score in predicting treatment outcomes for advanced HCC patients undergoing sorafenib treatment. Importance of accurate hepatic reserve evaluation for guiding therapy decisions in liver disease. Study on IGF CTP score in HCC treatment with Sorafenib, including insights on patient stratification and survival rates.

Researchers at Yale University created a new class of radiosensitizers for glioblastoma based on mibefradil, with improved potency and reduced off-target effects. They synthesized and tested 140 analogs, selecting top 12 for further in vivo studies. These analogs were shown to cross the blood-brain barrier and accumulate in mouse brain tissue, offering potential for enhanced radio sensitization in treating glioblastoma.

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 9. View the complete issue: https://www.oncotarget.com/archive/v12/i9/ Oncotarget Volume 12, Issue 9 features: COVER PAPER: “Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore” https://doi.org/10.18632/oncotarget.27933 EDITORIAL: “Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?” https://doi.org/10.18632/oncotarget.27904 (PDF Download) EDITORIAL: “Epigenetic effects of pharmacologic ascorbate” https://doi.org/10.18632/oncotarget.27911 (PDF Download) RESEARCH PAPER: “Activation of plasmacytoid dendritic cells promotes AML-cell fratricide” https://doi.org/10.18632/oncotarget.27949 RESEARCH PAPER: “Piperlongumine promotes death of retinoblastoma cancer cells” https://doi.org/10.18632/oncotarget.27947 RESEARCH PAPER: “A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer” https://doi.org/10.18632/oncotarget.27944 RESEARCH PAPER: “Down regulation of lactate dehydrogenase initiates apoptosis in HeLa and MCF-7 cancer cells through increased voltage-dependent anion channel protein and inhibition of BCL2” https://doi.org/10.18632/oncotarget.27950 REVIEW: “Multigene tests for breast cancer: the physician’s perspective” https://doi.org/10.18632/oncotarget.27948 Keywords - breast cancer, bladder cancer, glioblastoma, plasmacytoid dendritic cells, pharmacologic ascorbate, retinoblastoma, cancer cells, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Researchers from Knight Cancer Institute and Oregon Health and Science University conducted a study on midostaurin drug sensitivity in FLT3 mutated and wild-type acute myeloid leukemia patients. They identified genomic markers that predicted response to midostaurin, with a focus on ex vivo drug sensitivity screenings. The study aimed to understand the impact of different genomic alterations on midostaurin response, particularly in FLT3-ITD mutations.